Why Madrigal Pharmaceuticals, Inc. (MDGL) stock moved
Madrigal Pharmaceuticals, Inc. (MDGL) shares rose 4.6% to $467.54 as of October 20, 2026, a moderate gain from the prior close of $447.09. BestStocks flagged the session as a major change for MDGL. The move is tied to company news. Below, we break down what changed for MDGL, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Company News
Madrigal Pharmaceuticals scheduled Q3 2026 earnings release for November 3, 2026, before market open. Investors can expect revenue, pipeline progress, and cash runway updates from the clinical-stage biotech firm.
What it means for Madrigal Pharmaceuticals, Inc. investors
For Madrigal Pharmaceuticals, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Material positive event; Positive 4.6% session move. Weighing against that: Madrigal Pharmaceuticals (MDGL) declined 2.60% to $455.03, driven primarily by technical weakness and valuation reassessment rather than operational news; Madrigal announced publication in the Journal of Hepatology showing Rezdiffra maintains consistent efficacy across common MASH genetic risk variants (Globe Newswire), yet the stock fell 2.50% to $481.27. Wall Street's consensus price target sits at $686.44, implying +46.8% upside from $467.54. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality low (58/100). With earnings roughly 14 days out, the next report is the most likely near-term test of the move.
MDGL price reaction
MDGL last traded at $467.54, up $20.45 (+4.57%) from the previous close of $447.09. The session traded on 1.3× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $447.09 and $521.96, and it currently sits about 27% of the way up that band.
Bullish and bearish analyst opinions on Madrigal Pharmaceuticals, Inc. (MDGL)
The consensus analyst price target on Madrigal Pharmaceuticals, Inc. (MDGL) is $686.44, 46.8% above the recent $467.54. Over the past 90 days analysts logged 1 upgrade, 2 maintains, and 0 downgrades. Here is how the bullish and bearish cases on MDGL line up.
The bullish case
- Wall Street's consensus price target of $686.44 implies +46.8% upside from $467.54.
- The Street's most bullish target is $962.00 (+105.8%).
- 1 analyst upgrade in the past 90 days, most recently Wolfe Research to Outperform (2026-08-04).
- Material positive event.
- Positive 4.6% session move.
The bearish case
- Madrigal Pharmaceuticals (MDGL) declined 2.60% to $455.03, driven primarily by technical weakness and valuation reassessment rather than operational news.
- Madrigal announced publication in the Journal of Hepatology showing Rezdiffra maintains consistent efficacy across common MASH genetic risk variants (Globe Newswire), yet the stock fell 2.50% to $481.27.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 20, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for MDGL
In-depth MDGL event analyses
Frequently asked questions about MDGL
Why did Madrigal Pharmaceuticals, Inc. (MDGL) stock move?
MDGL rose 4.6% to $467.54. The move is associated with company news.
How much did MDGL stock rise?
MDGL gained 4.57% ($20.45) versus the prior close of $447.09, last trading at $467.54 on 1.3× average volume.
When is Madrigal Pharmaceuticals, Inc.'s next earnings date?
MDGL's next earnings report is estimated for 2026-11-03 — about 14 days away.
What is the analyst price target for MDGL?
The consensus analyst price target for MDGL is $686.44, about 46.8% above the current $467.54. Over the past 90 days, analysts recorded 1 upgrade, 2 maintains, and 0 downgrades.
How BestStocks tracks MDGL
This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for MDGL, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 20, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.